ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    elan alzheimer agitation

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01766336
Recruitment Status : Terminated
First Posted : January 11, 2013
Results First Posted : May 13, 2016
Last Update Posted : June 22, 2016
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by (Responsible Party):
Transition Therapeutics Ireland Limited

Brief Summary:
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Group 1 ELND005 Drug: Group 2 ELND005 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 296 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Study Start Date : January 2013
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Group 1 ELND005/ELND005
Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
Drug: Group 1 ELND005
Experimental: Group 2 PLACEBO/ELND005
Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.
Drug: Group 2 ELND005



Primary Outcome Measures :
  1. Number of Participants Experiencing Treatment Emergent Adverse Events [ Time Frame: 36 weeks ]
    To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Complete Week 12 visit of AG201
  • Both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests

Exclusion Criteria:

  • Is currently using any other investigational or experimental drugs or devices
  • Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01766336


  Show 46 Study Locations
Sponsors and Collaborators
Transition Therapeutics Ireland Limited
Elan Pharmaceuticals

Additional Information:
Responsible Party: Transition Therapeutics Ireland Limited
ClinicalTrials.gov Identifier: NCT01766336     History of Changes
Other Study ID Numbers: ELND005-AG251
2012-005524-15 ( EudraCT Number )
First Posted: January 11, 2013    Key Record Dates
Results First Posted: May 13, 2016
Last Update Posted: June 22, 2016
Last Verified: May 2016

Keywords provided by Transition Therapeutics Ireland Limited:
Agitation
Aggression
AD patients

Additional relevant MeSH terms:
Alzheimer Disease
Psychomotor Agitation
Aggression
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Behavioral Symptoms